Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Joint Budget Committee reviews and approves March 2025 pharmacy formulary, adds Stelara biosimilars
2898353 · April 8, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
Summary
The Joint Budget Committee reviewed and approved the March 2025 pharmacy formulary, including adding multiple biosimilars to Stelara and reclassifying certain medications; the changes are expected to take effect around June 1.
The Joint Budget Committee reviewed and approved the committee’s March 2025 pharmacy formulary, adding multiple biosimilars to the plan and reclassifying several medications.
Grant Wallace, director of the Employee Benefits Division, told committee members the packet (Exhibit C-1) reflected a routine…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
30-day money-back on paid plans
